Citigroup
LJPC

Citigroup’s La Jolla Pharmaceutical Company LJPC Stock Holding History

Citigroup’s Portfolio LJPC Stock Details LJPC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1
Closed – – 6605
2021
Q2 		$0 Sell
1
-1,193
-100% -$5.11K ﹤0.01% 6651
2021
Q1 		$5K Sell
1,194
-2,428
-67% -$13.4K ﹤0.01% 5926
2020
Q4 		$14K Buy
3,622
+2,656
+275% +$11.3K ﹤0.01% 6850
2020
Q3 		$4K Sell
966
-1,593
-62% -$6.6K ﹤0.01% 7186
2020
Q2 		$11K Sell
2,559
-3,286
-56% -$20K ﹤0.01% 7033
2020
Q1 		$25K Buy
5,845
+1,694
+41% +$10.7K ﹤0.01% 6556
2019
Q4 		$16K Sell
4,151
-1,226
-23% -$7.24K ﹤0.01% 7044
2019
Q3 		$47K Sell
5,377
-1,131
-17% -$10.7K ﹤0.01% 6179
2019
Q2 		$61K Buy
6,508
+712
+12% +$5.37K ﹤0.01% 6299
2019
Q1 		$38K Sell
5,796
-145,761
-96% -$949K ﹤0.01% 6574
2018
Q4 		$1.43M Buy
151,557
+81,079
+115% +$1.22M ﹤0.01% 3019
2018
Q3 		$1.42M Buy
70,478
+27,666
+65% +$723K ﹤0.01% 3101
2018
Q2 		$1.25M Sell
42,812
-4,594
-10% -$142K ﹤0.01% 3123
2018
Q1 		$1.41M Buy
47,406
+28,676
+153% +$925K ﹤0.01% 2925
2017
Q4 		$603K Buy
18,730
+6,483
+53% +$212K ﹤0.01% 3905
2017
Q3 		$426K Sell
12,247
-31,830
-72% -$1.02M ﹤0.01% 4281
2017
Q2 		$1.31M Buy
44,077
+41,790
+1,827% +$1.2M ﹤0.01% 3032
2017
Q1 		$68K Sell
2,287
-1,625
-42% -$41.5K ﹤0.01% 5496
2016
Q4 		$69K Buy
3,912
+3,422
+698% +$65.6K ﹤0.01% 5995
2016
Q3 		$12K Hold
490
– – ﹤0.01% 6483
2016
Q2 		$8K Sell
490
-11,362
-96% -$204K ﹤0.01% 6673
2016
Q1 		$248K Buy
11,852
+9,961
+527% +$178K ﹤0.01% 4878
2015
Q4 		$51K Buy
1,891
+1,399
+284% +$38.1K ﹤0.01% 5936
2015
Q3 		$14K Buy
492
+281
+133% +$8.85K ﹤0.01% 6283
2015
Q2 		$5K Buy
211
+193
+1,072% +$3.98K ﹤0.01% 6830
2015
Q1 		$0 Buy
+18
New +$365 ﹤0.01% 7877
2014
Q3 		– Sell
-11,225
Closed -$103K – 7689
2014
Q2 		$103K Hold
11,225
– – ﹤0.01% 4651
2014
Q1 		$121K Buy
+11,225
New +$110K ﹤0.01% 4819

Other funds holding LJPC

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HP
HealthInvest Partners Stockholm, Sweden $310M AUM 37.86% 1-Year Est. Return
KT
Kevin Tang $783 AUM 75.59% 1-Year Est. Return

Citigroup's LJPC Position: Q3 2021 in Review

Citigroup sold out of La Jolla Pharmaceutical Company (LJPC) in Q3 2021, closing a stake of 1 share.

Citigroup first reported a position in LJPC in Q1 2014 and held it in 28 quarters. The position peaked at $1.43M in Q4 2018. 54 funds tracked by Wall St. Rank hold LJPC as of Q3 2021.

  • Citigroup reported no remaining La Jolla Pharmaceutical Company position as of Q3 2021 after selling out during the quarter.
  • Citigroup sold 1 La Jolla Pharmaceutical Company share in Q3 2021.
  • Citigroup first reported a position in La Jolla Pharmaceutical Company in Q1 2014 and held it in 28 quarters.
  • Citigroup's La Jolla Pharmaceutical Company position peaked at $1.43M in Q4 2018.
  • 54 funds tracked by Wall St. Rank held La Jolla Pharmaceutical Company as of Q3 2021.

Based on Citigroup's 13F filing for Q3 2021, filed 10 Nov 2021.